Advances in the pulmonary delivery of poorly water-soluble drugs: Influence of solubilization on pharmacokinetic properties

Drug Development and Industrial Pharmacy

Volumn 36, Issue 1, 2010, Pages 1-30

  Tolman, Justin A ^a   Williams III, Robert O ^b  

^a CREIGHTON UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Absorption; Antifungals; Fentanyl; Inhalation; Peptide; Pharmacokinetics; Solubility; Steroids

Indexed keywords

ALPHA TOCOPHEROL; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHOLESTEROL; CITRATE SODIUM; CITRIC ACID; CORTICOSTEROID; CYCLODEXTRIN; CYCLOSPORIN; DISTEAROYLPHOSPHATIDIC ACID; EDETATE DISODIUM; EXCIPIENT; FENTANYL; FK 224; FLUTICASONE PROPIONATE; GIONA; ITRACONAZOLE; LACTOSE; OLEIC ACID; OLIGOPEPTIDE; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; RESPULES; SODIUM CHLORIDE; SORBITAN TRIOLEATE; SUCROSE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; ASTHMA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SOLUBILITY; DRUG TISSUE LEVEL; HUMAN; LUNG ASPERGILLOSIS; LUNG DISEASE; LUNG GRAFT REJECTION; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MICROCRYSTALLINE SUSPENSION; MYCOSIS; NEBULIZATION; NEBULIZER; NONHUMAN; REVIEW; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INHALATION; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; LUNG DISEASES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY;

EID: 74949083533     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903092319     Document Type: Review

References (124)

1. Sanders M. (2007). Inhalation therapy: An historical review. Prim Care Respir J, 16(2), 71-81.
2. Derom E, Thorsson L. (2001). Factors affecting the clinical outcome of aerosol therapy. In Bisgaard H, O'Callaghan C, Smaldone GC, eds. Drug delivery to the lung, vol.162. New York, NY: Marcel Dekker, Inc., 143-171
3. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. (2007). Particle engineering for pulmonary drug delivery. Pharm Res, 24(3):411-437
4. Yang W, Peters JI, Williams RO, III. (2008). Inhaled nanoparticles. A current review. Int J Pharm, 356(1-2):239-247
5. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. (2001). The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res, 2(4):198-209.
6. Gonda, I. (2006). Systemic delivery of drugs to humans via inhalation. J Aerosol Med, 19(1):47-53.
7. Patton JS, Byron PR. (2007). Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov, 6(1):67-74.
8. Patton JS, Fishburn CS, Weers JG. (2004). The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc, 1(4), 338-344
9. Bisgaard H, O'Callaghan C, Smaldone GC., eds. (2002). Drug delivery to the lung, vol.162. New York, NY: Marcel Dekker, Inc.
10. Byron PR. (1987). Pulmonary targeting with aerosols. Pharm Technol, 11(5):42, 44, 46, 48, 50, 52, 54, 56.
11. Cloutier MM. (2007). Respiratory physiology. Philadelphia, PA: Mosby.
12. Finney MJ, Anderson SD, Black JL. (1987). The effect of nonisotonic solutions on human isolated airway smooth muscle. Respir Physiol, 69(3):277-286
13. Martin GP, Bell AE, Marriott C. (1988). An in vitro method for assessing particle deposition from metered pressurized aerosols and dry powder inhalers. Int J Pharm, 44(1-3):57-63.
14. Bermejo M, Gonzalez-Alvarez I. (2008). How and where are drugs absorbed? In Gad SC, ed. Preclinical development handbook: ADME and biopharmaceutical properties. Hoboken, NJ: John Wiley & Sons, Inc., 249-280
15. Martinez MN, Amidon GL. (2002). A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J Clin Pharmacol, 42(6):620-643
16. Sakagami M. (2006). In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev, 58(9-10): 1030-1060
17. Miller FJ. (2000). Dosimetry of particles: critical factors having risk assessment implications. Inhal Toxicol, 12(Suppl. 3):389-395
18. Lipinski CA., Lombardo F, Dominy BW, Feeney PJ. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev, 23(1-3):3-25.
19. Pouton CW. (2006). Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci, 29(3-4), 278-287
20. Rasenack N, Mueller BW. (2005). Poorly water-soluble drugs for oral delivery-a challenge for pharmaceutical development: Part I: physicochemical and biopharmaceutical background/ strategies in pharmaceutical development. Pharm Ind, 67(3):323-326 (Pubitemid 40568839)
21. Stegemann S, Leveiller F, Franchi D, de Jong H, Linden H. (2007). When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci, 31(5):249-261
22. USP 31 - NF 26. (2008). Rockville, MD: The United States Pharmacopeial Convention.
23. Center for Drug Evaluation and Research (CDER). (1997). Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM 070237.pdf [accessed July 13, 2009].
24. Zhou H. (2008). Water-insoluble drugs and their pharmacokinetic behaviors. In: Liu R, ed. Water-insoluble drug formulation. 2nd ed. Hoboken, NJ: Taylor & Francis Ltd.
25. Drake RE, Laine GA, Allen SJ, Katz J, Gabel JC. (1987). A model of the lung interstitial-lymphatic system. Microvasc Res, 34(1):96-107.
26. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, et al. (2003). Inhalation of a dry powder tobramycin Pulmo- Sphere formulation in healthy volunteers. Chest, 124(1), 360-366
27. Lipworth BJ, Jackson CM. (2000). Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium. Drug Saf, 23(1):11-33.
28. Kelly HW. (1998). Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol, 102(4 Pt. 2):S36-51.
29. Edsbaecker S. (2001). Uptake, retention, and biotransformation of corticosteroids in the lung and airways. In: Schleimer RP, O'Byrne PM, Szefler SJ, Brattsand R, eds. Inhaled steroids in asthma: oftimizing effects in the airways, vol.163. New York, NY: Marcel Dekker, Inc., 213-244
30. Brindley C, Falcoz C, Mackie AE, Bye, A. (2000). Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus, and metered-dose inhaler in healthy volunteers. Clin Pharmacokin, 39(Suppl. 1):1-8.
31. Freiwald M, Valotis A, Kirschbaum A, McClellan M, Murdter T, Fritz P, et al. (2005). Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model. Respir Res, 6:21.
32. Hochhaus G. (2007). Pharmacokinetic and pharmacodynamic properties important for inhaled corticosteroids. Ann Allergy Asthma Immunol, 98(2 Suppl. 2):S7-15.
33. Kinnarinen T, Jarho P, Jaervinen K, Jaervinen T. (2003). The in vitro pulmonary deposition of a budesonide/gamma -cyclodextrin inclusion complex. J Incl Phenom Macrocycl Chem, 44(1-4):97-100.
34. Laehelmae S, Kirjavainen M, Kela M, Herttuainen J, Vahteristo M, Silvasti M, et al. (2005). Equivalent lung deposition of budesonide in vivo: A comparison of dry powder inhalers using a pharmacokinetic method. Br J Clin Pharmacol, 59(2):167-173
35. Saari M, Vidgren MT, Koskinen MO, Turjanmaa VMH, Nieminen MM. (1999). Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int J Pharm, 181(1):1-9.
36. Mollmann H, Balbach S, Hochhaus G, Barth J, Derendorf H. (1995). Pharmacokinetic-pharmacodynamic correlations of corticosteroids. In: Derendorf H, Hochhaus G, eds. Handbook of pharmacokinetic/pharmacodynamic correlation. Boca Raton, FL: CRC Press, 323-362
37. Lipworth BJ. (1996). Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol, 42(6):697-705.
38. Moelmann H, Wagner M, Krishnaswami S, Dimova H, Tang Y, Falcoz C, et al. (2001). Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol, 41(12):1329-1338
39. Mortimer KJ, Harrison TW, Tang Y, Wu K, Lewis S, Sahasranaman S, et al. (2006). Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br J Clin Pharmacol, 62(4), 412-419
40. Thorsson L, Dahlstroem K, Edsbaecker S, Kaellen A, Paulson J, Wiren JE. (1997). Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol, 43(2):155-161
41. Thorsson L, Edsbacker S, Kallen A, Lofdahl CG. (2001). Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol, 52(5):529-538
42. Whelan GJ, Blumer JL, Martin RJ, Szefler SJ. (2005). Fluticasone propionate plasma concentration and systemic effect: Effect of delivery device and duration of administration. J Allergy Clin Immunol, 116(3):525-530
43. Argenti D, Shah B, Heald D. (2000). A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration. J Clin Pharmacol, 40(5):516-526
44. Bisgaard H, Nikander K, Munch E. (1998). Comparative study of budesonide as a nebulized suspension vs pressurized metered-dose inhaler in adult asthmatics. Respir Med, 92(1):44-49
45. Kraft WK, Steiger B, Beussink D, Quiring JN. Fitzgerald N, Greenberg HE, et al. (2004). The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol, 44(1):67-72.
46. Shrewsbury SB, Bosco AP, Uster PS. (2009). Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int J Pharm, 365(1-2):12-17
47. Hill M. (2007). US patent no. US 2007/0197487 A1. USPTO.
48. Daley-Yates PT, Price AC, Sisson JR, Pereira A. Dallow N. (2001). Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol, 51(5):400-409
49. Esposito-Festen JE, Zanen P, Tiddens HAWM, Lammers JWJ. (2007). Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. Br J Clin Pharmacol, 64(3):328-334
50. Lim JGP, Shah B, Rohatagi S, Bell A. (2006). Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships. Am J Ther, 13(1):32-42.
51. Argenti D, Shah B, Heald D. (1999). A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. J Clin Pharmacol, 39(7):695-702.
52. Hintz RJ., Johnson KC. (1989). The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm, 51(1):9-17.
53. Johnson KC. (2007). Dissolution: Fundamentals of in vitro release and the biopharmaceutics classification system. Drugs Pharm Sci, 165(Pharmaceutical Product Development): 1-28.
54. Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y, et al. (2008). Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res, 25(10):2334-2344
55. Sigfridsson K, Forssen S, Hollaender P, Skantze U, de Verdier J. (2007). A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. Eur J Pharm Biopharm, 67(2):540-547
56. Brown TER, Chin TWF. (2008). Superficial fungal infections. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A pathophysiologic approach. 6th ed. Chicago, IL: McGraw-Hill.
57. Carver PL. (2008). Invasive fungal infections. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. eds. Pharmacotherapy: A pathophysiologic approach. 6th ed. Chicago, IL: McGraw-Hill.
58. Kauffman CA. (2006). Fungal infections. Proc Am Thorac Soc, 3(1):35-40.
59. Patterson TF. (2005). Advances and challenges in management of invasive mycoses. Lancet, 366(9490):1013-1025
60. Clemons KV, Stevens DA. (2005). The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med Mycol, 43(Suppl. 1):S101-10.
61. Boucher HW, Groll AH, Chiou CC, Walsh TJ. (2004). Newer systemic antifungal agents: Pharmacokinetics, safety and efficacy. Drugs, 64(18):1997-2020.
62. Wiebe V, Karriker M. (2005). Therapy of systemic fungal infections: A pharmacologic perspective. Clin Tech Small Anim Pract, 20(4):250-257
63. Yalkowsky SH, He Y. (2003). Handbook of aqueous solubility data. Boca Raton, FL: CRC Press.
64. Bennett JE. (2006). Antimicrobial agents: Antifungal agents. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York, NY: The McGraw-Hill Companies, Inc.
65. Miyake K, Irie T, Arima H, Hirayama F, Uekama K, Hirano M, et al. (1999). Characterization of itraconazole/2-hydroxypropylbeta- cyclodextrin inclusion complex in aqueous propylene glycol solution. Int J Pharm, 179(2):237-245
66. Rhee Y-S, Park C-W, Nam T-Y, Shin Y-S, Chi S-C, Park E-S. (2007). Formulation of parenteral microemulsion containing itraconazole. Arch Pharm Res, 30(1):114-123
67. Gold W, Stout HA., Pagano JF, Donovick R. (1956). Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. Antibiot Ann, 579-585
68. Bennett JE. (2001). Antimicrobial agents: antifungal agents. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's the pharamcological basis of therapeutics. 10th ed. Chicago, IL: McGraw-Hill, 1295-1299
69. Graybill JR, Revankar SG, Patterson TF. (1998). Antifungal agents and antifungal susceptibility testing. In: Ajello L, Hay RJ, eds. Medical mycology, 9th ed., vol.4. New York, NY: Oxford University Press, Inc., 163-165
70. Brajtburg J, Powderly WG, Kobayashi GS., Medoff G. (1990). Amphotericin B: Current understanding of mechanisms of action. Antimicrob Agents Chemother, 34(2), 183-188
71. Diot P. Rivoire B, Le Pape A, Lemarie E, Dire D, Furet Y, et al. (1995). Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J, 8(8):1263-1268
72. Koizumi T, Kubo K, Kaneki T, Hanaoka M, Hayano T, Miyahara T, et al. (1998). Pharmacokinetic evaluation of amphotericin B in lung tissue: Lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B. Antimicrob Agents Chemother, 42(7):1597-1600
73. Lowry CM, Marty FM, Vargas SO, Lee JT., Fiumara K, Deykin A, et al. (2007). Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: A retrospective study. Transpl Infect Dis, 9(2):121-125
74. Marra F, Partovi N, Wasan KM, Kwong EH, Ensom MHH, Cassidy SM, et al. (2002). Amphotericin B disposition after aerosol inhalation in lung transplant recipients. Ann Pharmacother, 36(1):46-51.
75. Monforte V, Roman A, Gavalda J, Lopez R, Pou L, Simo M, et al. (2003). Nebulized amphotericin B concentration and distribution in the respiratory tract of lung transplanted patients. Transplantation, 75(9):1571-1574
76. Ruijgrok EJ, Vulto AG, Van Etten EWM. (2000). Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): Aerosol characteristics and invivo amphotericin B deposition in rats. J Pharm Pharmacol, 52(6):619-627
77. Rogers TL, Nelsen AC, Sarkari M, Young TJ, Johnston KP, Williams RO, III. (2003). Enhanced aqueous dissolution of a poorly water soluble drug by novel particle engineering technology: Spray-freezing into liquid with atmospheric freezedrying. Pharm Res, 20(3), 485-493
78. Overhoff KA, Engstrom JD, Chen B, Scherzer BD, Milner TE, Johnston KP, et al. (2007). Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs. Eur J Pharm Biopharm, 65(1):57-67.
79. Hu J, Johnston KP, Williams RO, III. (2004). Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm, 30(3):233-245
80. Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, et al. (2008). High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm, 361(1-2):177-188
81. Purvis T, Vaughn Jason M, Rogers True L, Chen X, Overhoff Kirk A, Sinswat P, et al. (2006). Cryogenic liquids, nanoparticles, and microencapsulation. Int J Pharm, 324(1), 43-50.
82. Hoeben BJ, Burgess DS, McConville JT, Najvar LK, Talbert RL, Peters JI, et al. (2006). In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother, 50(4):1552-1554
83. McConville JT, Overhoff KA, Sinswat P, Vaughn JM, Frei BL, Burgess DS, et al. (2006). Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res, 23(5):901-911
84. Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL, et al. (2006). Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm, 63(2):95-102.
85. Ewing P, Blomgren B, Ryrfeldt A, Gerde P. (2006). Increasing exposure levels cause an abrupt change in the absorption and metabolism of acutely inhaled benzo(a)pyrene in the isolated, ventilated, and perfused lung of the rat. Toxicol Sci, 91(2):332-340
86. Bruesewitz C, Schendler A, Funke A, Wagner T, Lipp R. (2007). Novel poloxamer-based nanoemulsions to enhance the intestinal absorption of active compounds. Int J Pharm, 329(1-2), 173-181
87. Wong SM, Kellaway IW, Murdan S. (2006). Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm, 317(1):61-68
88. Vermeij P, Blok D. (1996). New peptide and protein drugs. Pharm World Sci, 18(3):87-93.
89. Goldberg M, Gomez-Orellana I. (2003). Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov, 2(4):289-295
90. Kumar TRS, Soppimath K, Nachaegari SK. (2006). Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol, 7(4):261-276
91. Morishita M, Peppas NA. (2006). Is the oral route possible for peptide and protein drug delivery? Drug Discov Today, 11(19 & 20):905-910
92. Shoyele SA, Slowey A. (2006). Prospects of formulating proteins/ peptides as aerosols for pulmonary drug delivery. Int J Pharm, 314(1):1-8.
93. Blot F, Faurisson F, Bernard N, Sellam S, Friard S, Tavakoli R, et al. (1999). Nebulized cyclosporine in the rat: Assessment of regional lung and extrapulmonary deposition. Transplantation, 68(2):191-195
94. Mitruka SN, Pham SM, Zeevi A, Li S, Cai J, Burckart GJ, et al. (1998). Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation. J Thorac Cardiovasc Surg, 115(1):28-37.
95. Mitruka SN, Won A, McCurry KR, Zeevi A, McKaveney T, Venkataramanan R, et al. (2000). In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine. J Heart Lung Transplant, 19(10):969-975
96. Burckart GJ, Smaldone GC., Eldon MA, Venkataramanan R, Dauber J, Zeevi A, et al. (2003). Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharm Res, 20(2), 252-256
97. Keenan R, Iacono A, Dauber J, Zeevi A, Yousem S, Ohori N, et al. (1997). Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg, 113(2):335-340
98. Wang T, Noonberg S, Steigerwalt R, Lynch M, Kovelesky RA, Rodriguez CA., et al. (2007). Preclinical safety evaluation of inhaled cyclosporine in propylene glycol. J Aerosol Med, 20(4):417-428
99. Letsou G, Safi H, Reardon M, Ergenoglu M, Li Z, Klonaris C, et al. (1999). Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann Thorac Surg, 68(6):2044-2048
100. Waldrep JC, Arppe J, Jansa KA, Vidgren M. (1998). Experimental pulmonary delivery of cyclosporin A by liposome aerosol. Int J Pharam, 160(2):239-249
101. Tam JM, McConville JT, Williams RO, III, Johnston KP. (2008). Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci, 97(11):4915-4933
102. Adell A. (2004). Antidepressant properties of substance P antagonists: Relationship to monoaminergic mechanisms? Curr Drug Targets: CNS Neurol Disord, 3(2):113-121
103. Diemunsch P, Grelot L. (2003). Potential of substance P antagonists as antiemetics. Antiemetic Ther, 78-97. http://content. karger.com/ProdukteDB/ produkte.asp?Aktion=ShowPDF &ArtikelNr=71407&ProduktNr= 228876&filename=71407.pdf [accessed July 13, 2009].
104. Henry JL. (1993). Substance P and inflammatory pain: Potential of substance P antagonists as analgesics. Agents Actions Suppl, 41(Inflammatory Disease Therapy):75-87.
105. Nakate T, Yoshida H, Ohike A, Tokunaga Y, Ibuki R, Kawashima Y. (2003b). Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with betacyclodextrin. Eur J Pharm Biopharm, 55(2):147-154
106. Nakate T, Yoshida H, Ohike A, Tokunaga Y, Ibuki R, Kawashima Y. (2003). Comparison of the lung absorption of FK224 inhaled from a pressurized metered dose inhaler and a dry powder inhaler by healthy volunteers. Eur J Pharm Biopharm, 56(3):319-325
107. Stavchansky S, Martin A, Loper A. (1979). Solvent system effects on drug absorption. Res Commun Chem Pathol Pharmacol, 24(1):77-85.
108. Krishna R, Webb MS., St. Onge G, Mayer LD. (2001). Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther, 298(3):1206-1212
109. Mallick S, Pattnaik S, Swain K, De PK. (2007). Current perspectives of solubilization: Potential for improved bioavailability. Drug Dev Ind Pharm, 33(8):865-873
110. Wax PM, Becker CE, Curry SC. (2003). Unexpected 'gas' casualties in Moscow: A medical toxicology perspective. Ann. Emerg. Med. 41(5):700-705
111. Hung O, Pliura D. (2008). Comparative phase I PK study of aerosolized free and liposome-encapsulated fentanyl (AeroLEF™) demonstrates rapid and extended plasma fentanyl concentrations following inhalation. Paper presented at the 27th annual scientific meeting of the American Pain Society.
112. Hung OR, Whynot SC, Varvel JR, Shafer SL. (1995). Pharmacokinetics of inhaled liposome-encapsulated fentanyl. Anesthesiology, 83(2):277-284
113. Mather LE., Woodhouse A, Ward ME, Farr SJ, Rubsamen RA, Eltherington LG. (1998). Pulmonary administration of aerosolized fentanyl: Pharmacokinetic analysis of systemic delivery. Br J Clin Pharmacol, 46(1):37-43.
114. LAB International Inc. (2005, October 26). LAB International announces positive preliminary results from additional Phase 1 fentanyl TAIFUN® trial, http://www.akelapharma.com/ modules.php?op=modload&name=News&file= article&sid=17 [accessed December 28, 2008].
115. Overhoff KA, Clayborough R, Crowley M. (2008). Review of the TAIFUN multidose dry powder inhaler technology. Drug Dev Ind Pharm, 34(9):960-965
116. Miyake K, Arima H, Irie T, Hirayama F, Uekama K. (1999). Enhanced absorption of cyclosporin A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and -noncannulated rats. Biol Pharm Bull, 22(1):66-72.
117. Porter CJH, Pouton CW, Cuine JF, Charman WN. (2008). Enhancing intestinal drug solubilization using lipid-based delivery systems. Adv Drug Deliv Rev, 60(6):673-691
118. Hickey AJ. (2002). Delivery of drugs by the pulmonary route. In: Banker GS, Rhodes CT, eds. Drugs and the Pharmaceutical Sciences, 4th ed. vol.121. New York, NY: Marcel Dekker, 479-499
119. Winkler J, Hochhaus G, Derendorf H. (2004). How the lung handles drugs: Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc, 1(4):356-363
120. Williams AC, Barry BW. (2004). Penetration enhancers. Adv Drug Deliv Rev, 56(5):603-618
121. Jarabek A, Asgharian B, Miller F. (2005). Dosimetric adjustments for interspecies extrapolation of inhaled poorly soluble particles (PSP). Inhal Toxicol, 17(7-8):317-334
122. Carrier RL, Miller LA, Ahmed I. (2007). The utility of cyclodextrins for enhancing oral bioavailability. J. Control Release, 123(2):78-99.
123. Challa R, Ahuja A, Ali J, Khar RK. (2005). Cyclodextrins in drug delivery: An updated review. AAPS Pharm Sci Tech, 6(2):E329-57.
124. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. (2002). Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother, 46(3):834-840